Akero’s cash, cash equivalents and short and long-term marketable securities as of June 30, 2025, were $1,086.2 million. Akero believes that its cash, cash equivalents and short and long-term marketable securities will be sufficient to fund its current operating plan into 2028.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AKTX:
- Akari Therapeutics releases ‘What This Means’ segment for investors
- Akari Therapeutics reiterates commitment to research on PH1
- Akari Therapeutics ‘just getting started,’ initiated with a Buy at Maxim
- Akari Therapeutics initiated with a Buy at Maxim
- Akari Therapeutics Shareholders Approve Key AGM Resolutions